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Abstract
Background: In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the
only systemic treatment that has been shown to increase overall survival. However, similar to other tyrosine kinase
inhibitors, most patients achieve disease stabilisation radiologically, and only 2–3% of patients achieve a partial
response. Recent exploratory subgroup analyses of the large phase 3 trials have demonstrated that patients with
chronic hepatitis C virus (HCV) infection associated HCC survive longer than those who are negative for HCV. The
mechanism underlying this currently remains unknown. A small number of cases of complete response to sorafenib
treatment have now been reported worldwide, however a prolonged response has only been reported in 2 cases,
both of whom had HCV-related HCC.
Case presentation: A 55 year old gentleman was diagnosed with hepatocellular carcinoma and concomitant
chronic hepatitis C viral infection. He progressed following transarterial chemoemoblisation treatment and was
commenced on sorafenib treatment. His serum alphafetoprotein level normalised within 2 months of treatment
and he achieved an almost complete radiological response. This response was maintained for 20 months before
the patient progressed. A 75 year old lady was diagnosed with advanced hepatocellular carcinoma and
concomitant chronic hepatitis C viral infection. She was commenced on sorafenib treatment but required early
dose reductions due to palmar plantar erythrodysesthesia, and liver decompensation. Despite this she achieved an
excellent serological and radiological response that was maintained for 24 months.
Conclusions: Our two cases show that patients with HCV-associated HCC can attain excellent responses to
sorafenib treatment that is durable. Furthermore, such exceptional responses can be achieved even with dose
reductions and treatment breaks.
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Background
Hepatocellular carcinoma (HCC) is the 5th most com-
mon cancer worldwide, and the 3rd most common cause
of cancer death. It often occurs on a background of
chronic liver disease, including chronic hepatitis C
(HCV) or hepatitis B (HBV) viral infection, and alco-
holic liver disease [1].
Sorafenib, a multikinase inhibitor, is the only systemic
treatment shown to increase overall survival in those
with advanced HCC [2, 3]. However only 2–3% of pa-
tients achieve a partial response to sorafenib, with most
patients achieving disease stabilisation.
Here we report two cases with advanced hepatocellular
carcinoma and concomitant chronic hepatitis C viral in-
fection, who achieved almost complete radiological re-
sponses to sorafenib treatment for a prolonged period.
There are only 2 other reported cases in the literature
reporting prolonged responses following sorafenib treat-
ment [4, 5].
Chronic HCV infection is one of most common causes
of HCC in Western countries. Despite the recent intro-
duction of effective antiviral HCV therapy, the incidence
of HCV-associated HCC is predicted to increase over
the next few years due to the epidemic of undiagnosed
chronic HCV infection [1]. There is now increasing evi-
dence to suggest that patients with HCV-related HCC
may attain superior survival benefit with sorafenib com-
pared to patients who are negative for HCV. An explora-
tory subgroup analysis of the SHARP trial reported that
patients with HCV-related HCC treated with sorafenib
had a longer median overall survival compared to those
with alcohol- or HBV-related HCC (14.0 vs 10.3 vs
9.7 months, respectively) [6]. In the phase III trial com-
paring sunitinib and sorafenib in patients with advanced
HCC, median overall survival was superior in sorafenib
treated patients, particularly in those with chronic HCV
infection (17.6 vs 9.2 months) [7]. Similar results were
was also reported in the phase III trial comparing briva-
nib and sorafenib; exploratory subgroup analyses dem-
onstrated that the HCV positive subgroup of the
sorafenib arm had a longer overall survival than the
hepatitis C negative participants who received sorafenib
(12.9 vs. 9.3 months) [8].
The precise mechanism underlying the possible higher
efficacy of sorafenib in patients with chronic HCV infec-
tion currently remains unclear. In vitro, it has been
shown that cellular expression of full length HCV en-
hances sensitivity to sorafenib. This was due to modula-
tion of microRNA expression by the viral proteins,
which in turn enhances apoptosis through downregula-
tion of the anti-apoptotic protein Mcl-1 [9].
There is also increasing evidence outlining the mech-
anism by which sorafenib interacts with the hepatitis C
virus. In vitro, sorafenib has been shown to inhibit HCV
infection in a dose-dependent manner [10]. Multiple
steps in the HCV infectious cycle appear to be affected,
including inhibition of viral replication by blocking the
c-Raf pathway that is normally activated by the virus,
impaired secretion of HCV particles, and potent inhib-
ition of viral entry and HCV cell-to-cell transmission
[10, 11]. Further studies have researched whether sorafe-
nib may have benefit in treating chronic HCV infection
– however a small study of 33 patients being treated for
HCC with sorafenib failed to show any significant
change in measured viral load [12]. Similarly in our 2
cases, sorafenib treatment was not associated with any
reduction in the HCV viral load.
Case presentation 1
A 55 year old gentleman was diagnosed with hepatocel-
lular carcinoma in September 2012, following investiga-
tions for deranged liver function tests. Magnetic
resonance imaging (MRI) of the abdomen demonstrated
a 4.5 cm liver lesion, with arterial phase hyperenhance-
ment and venous phase washout, with an adjacent satel-
lite nodule and invasion into a portal vein branch. The
background liver appeared cirrhotic, and the spleen was
enlarged. His serum alpha fetoprotein (AFP) was
1751kU/L, and a viral hepatitis screen showed chronic
hepatitis C virus (HCV) infection and evidence of previ-
ous hepatitis B viral infection. His HCV viral load at
baseline was 606926 IU/mL. He had well compensated
liver function (Child Pugh class A) and an Eastern Co-
operative Oncology Group (ECOG) performance status
of zero.
He was treated with transarterial chemoembolisation
(TACE) as the invasion into his branch portal vein was
non-occlusive, but his computed tomography (CT) scan
4 weeks post-TACE demonstrated disease progression,
with an increase in size and enhancement of the primary
liver lesion, progression of the branch portal vein inva-
sion and multiple new abdominal, para-aortic and medi-
astinal lymphadenopathy (Fig. 1a).
He started treatment with sorafenib in January 2013,
achieving a maintenance dose of 600 mg daily after
2 months. He achieved an excellent serological response;
his serum AFP level fell from a baseline value of 348kU/
L to 5kU/L within 2 months and remained suppressed
thereafter. This was associated with an excellent radio-
logical response: CT imaging after 3 months of treat-
ment showed a significant decrease in the size of the
primary liver lesion and the lymphadenopathy (Fig. 1b).
Follow-up CT imaging after 6 months of treatment dem-
onstrated disappearance of all measurable disease apart
from a residual lymph node adjacent to the caudate lobe
(Fig. 1c). He maintained his excellent serological and
radiological response for a further 14 months, until pro-
gressive disease was seen on repeat CT imaging in
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August 2014. He received a total of 20 months of treat-
ment with sorafenib. Sorafenib had no effect on the pa-
tient’s HCV viral load, which remained significantly
elevated during this period. The patient entered a sec-
ond line clinical trial and remained alive for a further
11 months following discontinuation of sorafenib.
Case presentation 2
A 75 year old lady was diagnosed with advanced hepato-
cellular carcinoma in June 2013 following investigations
for low platelet count. A CT scan of the liver showed a
12 cm tumour in the left lobe with arterial phase hyper-
enhancement and venous phase washout, and left portal
vein invasion (Fig. 2a). The background liver appeared
cirrhotic. Her serum AFP level was 372 kU/L. A viral
hepatitis screen confirmed chronic hepatitis C virus in-
fection, with a low viral load (114 IU/mL). She had well
compensated liver function (Child Pugh class A) and an
ECOG performance status of 1.
She started sorafenib in July 2013, at a dose of 400 mg
twice daily. After 7 days she developed grade 2 palmar-
plantar erythrodysesthesia and treatment was paused and
then restarted at reduced dose of 400 mg daily. She devel-
oped grade 2 hand-foot skin toxicity again and her sorafe-
nib dose was thus reduced further to 200 mg daily, which
was well tolerated. Repeat CT imaging after 3 months of
treatment showed stable disease, however her serum AFP
level had risen to 1574 kU/L. Her dose of sorafenib was
cautiously increased. Over the next 2 months her serum
AFP level declined rapidly to 6 kU/L.
Following this her liver synthetic function deteriorated
and she decompensated with recurrent episodes of hep-
atic encephalopathy and ascites. Her treatment was
paused for 4 months. Throughout this period her serum
AFP level remained below 13kU/L. On review in March
2014 her liver synthetic function had improved (Child
Pugh class B7), and she restarted low dose sorafenib. CT
imaging in March showed ongoing stable disease despite
the 4 month treatment break. Following resumption of
sorafenib, serial CT scans showed reduction in the size
of the liver lesion, with no tumour enhancement seen on
her repeat imaging in December 2014 (Fig. 2b). She
maintains her excellent serological and radiological re-
sponse to date, 24 months after first starting sorafenib.
Fig. 1 Case 1 response to sorafenib. a. Triple phase CT of the liver 07/12/2012. Primary HCC with arterial phase enhancement (# top panel) and portal
venous washout (§ middle panel) with involved lymph node between portal vein and IVC (bottom panel *). b. Triple phase CT of the liver 03/04/2013.
Primary HCC with reduced arterial phase enhancement (# top panel) and portal venous washout (§ middle panel) with two cystic areas. Reduction in
size of lymph node (bottom panel *). c. Triple phase CT of the liver 15/07/2013. No arterial phase enhancement (top panel) or portal phase washout
(middle panel) reflecting disappearance of tumour. Residual cystic areas. Sustained reduction in size of lymph node (bottom panel *)
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Her HCV viral load initially increased to 4000 IU/mL
after starting sorafenib and remains elevated.
Conclusions
In patients with advanced HCC, sorafenib is the only sys-
temic treatment that has been shown to increase overall
survival [2, 3]. Sorafenib is an orally active, multikinase in-
hibitor that inhibits tumour angiogenesis and cell prolifera-
tion by blocking cell surface tyrosine kinases such as
vascular endothelial growth factor receptor-2/3 (VEGFR-2/
3) and platelet derived growth factor receptor beta, as well
as downstream signalling pathways involving the serine/
threonine kinases Raf-1 and B-Raf [13]. Its efficacy in treat-
ing HCC has been demonstrated in 2 randomised phase III
trials [2, 3]. The SHARP trial, undertaken in patients with
advanced HCC in Western countries, showed that patients
with advanced hepatocellular carcinoma treated with soraf-
enib had a significant improvement in overall survival
(10.7 months vs. 7.9 months, p < 0.001) and radiological
time to progression (5.5 months vs. 2.8 months, p < 0.001)
when compared to placebo [2]. The Asia-Pacific trial also
showed that sorafenib significantly prolonged overall sur-
vival (6.5 months vs. 4.2 months, hazard ratio 0.68, p =
0.014) compared to placebo, in patients from the Asia-
Pacific region [3]. In both trials a partial response was ob-
served in only a small minority of patients (2 and 3% re-
spectively) and no complete responses were seen.
A small number of cases of complete response to sorafe-
nib treatment have now been reported worldwide [4, 5,
14–17], however a prolonged response (>18 months) has
only been reported in 2 cases, both of whom had HCV-
related HCC [4, 5]. Both of our cases also had HCV-
related HCC and demonstrated prolonged responses (20
and 24 months, respectively) to sorafenib treatment. The 2
cases presented here add to the accumulating evidence that
patients with HCV-related HCC may attain superior sur-
vival benefit with sorafenib compared to patients who are
negative for HCV. The second case is particularly note-
worthy, because the prolonged response was achieved even
with dose reductions and a treatment break (due to de-
compensation), and highlights that even with dose reduc-
tions, significant response to sorafenib can be achieved.
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